BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to treat cancer. Get up to date with the BeiGene hematology pipeline and clinical trials.

A short summary describing a next-generation BTK inhibitor with sustained and potent activity at disease sites and low off-target kinase inhibition.

Poster presented at ASH 2022 evaluating a new therapeutic approach for patients with B-cell malignancies who received prior BTKi treatment and became intolerant.

Poster presented at ASH 2022 describing the potential for combining BCL2i and BTKi in patients with non-Hodgkin's lymphoma (NHL), including separate cohorts for mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia (WM).